Physician profile
Ramprakash Devadoss
NPI 1487918017
$5,922.17
in general payments reported to CMS, 2019-2025
24 companies · $1,940 in 2025
The $1,940 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $222 · 2021: $671 · 2022: $224 · 2023: $1,175 · 2024: $1,420 · 2025: $1,940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,445 · Travel and Lodging: $2,090.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,444.74 |
| Travel and Lodging | $2,090.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,451.51 | 2021-2025 | Synergy, General - Vascular Access, Avvigo Guidance System |
| Abbott Laboratories | $1,434.09 | 2021-2025 | Ultreon, Coroflow, Optis |
| Abiomed | $636.15 | 2020-2025 | Impella |
| Edwards Lifesciences Corporation | $361.76 | 2021-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Teleflex LLC | $357.01 | 2022-2025 | Guideliner, Turnpike, Vascband |
| Medtronic, INC. | $327.53 | 2021-2025 | Hawkone, Corevalve Evolut R, Onyx Frontier |
| Medtronic Vascular, INC. | $327.26 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $183.48 | 2021-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $163.37 | 2019-2024 | Lifevest |
| Terumo Medical Corporation | $123.59 | 2021 | |
| Shockwave Medical, INC | $116.34 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Zoll Circulation INC | $80.45 | 2023 | Downstream Cartridge, Therox Ds2 Console, Catheter |
| Actelion Pharmaceuticals US, INC. | $77.84 | 2024 | Uptravi, Opsumit |
| Cardiovascular Systems INC. | $50.15 | 2022 | |
| Janssen Pharmaceuticals, INC | $39.14 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $31.70 | 2023 | Lifesparc |
| Astrazeneca Pharmaceuticals Lp | $30.84 | 2022-2023 | Farxiga |
| W. L. Gore & Associates, INC. | $27.38 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $21.33 | 2023 | Inpefa |
| Angiodynamics, INC. | $19.79 | 2023 | Angiovac |
| Bayer Healthcare Pharmaceuticals INC. | $19.38 | 2023 | |
| Amgen INC. | $18.81 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.48 | 2022 | |
| Pfizer INC. | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramprakash Devadoss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.